Degradation Products of Extracellular Matrix Affect Cell Migration and Proliferation

Citations Over TimeTop 1% of 2008 papers

Abstract

Biologic scaffolds composed of extracellular matrix (ECM) are utilized in numerous regenerative medicine applications to facilitate the constructive remodeling of tissues and organs. The mechanisms by which the host remodeling response occurs are not fully understood, but recent studies suggest that both constituent growth factors and biologically active degradation products derived from ECM play important roles. The objective of the present study was to determine if degradation of ECM scaffold materials in vitro by methods that are biochemically and physiologically relevant can yield products that possess chemotactic and/or mitogenic activities for fully differentiated mammalian endothelial cells and undifferentiated multipotential progenitor cells. ECM harvested from porcine urinary bladder was degraded enzymatically with pepsin/hydrochloric acid or papain. The ECM degradation products were tested for chemoattractant properties utilizing either 48-well chemotaxis filter migration microchambers or fluorescence-based filter migration assays, and were tested for mitogenic properties in cell proliferation assays. Results showed that ECM degradation products possessed chemotactic and mitogenic activities for multipotential progenitor cells and that the same degradation products inhibited both chemotaxis and proliferation of differentiated endothelial cells. These findings support the concept that degradation products of ECM bioscaffolds are important modulators of the recruitment and proliferation of appropriate cell types during the process of ECM scaffold remodeling.

Related Papers

• → In Situ Cross-Linkable Hydrogels as a Dynamic Matrix for Tissue Regenerative Medicine(2018)49 cited
• → Tissue Engineering and Regenerative Medicines: An Interdisciplinary Understanding(2020)5 cited
• The Birth and Development of Tissue Engineering(2014)
• [Significance of tissue engineering in clinical practice of regenerative medicine].(2003)
• Regenerative Medicine: A Scaffold Therapy in Heart Regeneration Through Tissue Engineering.(2021)